女性SLE患者血清性激素水平研究

为了探讨性激素在ＳＬＥ发病中的作用,我们采用放射免疫法检测了２０例女性ＳＬＥ患者血清睾酮（Ｔ）、游离睾酮（ＦＴ）、二氢睾酮（ＤＨＴ）、脱氢表雄酮（ＤＨＥＡ）、雌二醇（Ｅ２）、孕酮（Ｐｒ）和泌乳素（ＰＲＬ）水平。结果发现患者血清Ｔ、ＦＴ、ＤＨＴ、ＤＨＥＡ、Ｐｒ明显低于正常对照,ＰＲＬ明显高于正常对照（Ｐ〈０．０５）,Ｅ２无显著差异（Ｐ〉０．０５）;未使用皮质类固醇治疗的患者血清雄激素水平也显著降低（     

女性痤疮血清性激素及胰岛素样生长因子-1的研究

目的：探讨性激素和生长激素在痤疮发病中的作用。方法：采用放射免疫法检测了３０例女性痤疮患者血清睾酮（Ｔ）游离睾酮（ＦＴ）、二氢睾酮（ＤＨＴ）、脱氢表雄酮（ＤＨＥＡ）、雌二醇（Ｅ２）、孕酮（Ｐｒ）、泌乳素（ＰＲＬ）和胰岛素样生长因子－１（ＩＧＦ－１）水平。结果：女性痤疮患者血清ＤＨＴ、ＤＨＥＡ、ＩＧＦ－１明显高于正常对照（Ｐ〈０．０５）,其余指标无显著差异;轻、中、重型痤疮的激素水平无显著差异;ＩＧＦ－１与性激素水平无显著相关（Ｐ〉０．０５）。结论：性激素尤其雄激素和生长激素在痤疮的发病中起了一定的作用。     

系统性红斑狼疮患者生长激素及其受体和泌乳素水平的研究

用放射免疫分析法（ＲＩＡ）和放射受体分析法（ＲＲＡ）检测３４例系统性红斑狼疮（ＳＬＥ）患者和２０例正常人血清生长激素（ＧＨ）和泌乳素（ＰＲＬ）水平及其生长激素受体（ＧＨ－Ｒ）容量。结果显示ＳＬＥ患者血清ＧＨ和ＰＲＬ水平均显著高于正常对照组，血清ＧＨ－Ｒ容量与正常对照组相比无显著差异。ＳＬＥ患者血清ＧＨ增高与病情活动度和抗ｄｓＤＮＡ抗体水平增高密切相关，而ＰＲＬ无此关系。我们推测在ＳＬＥ的发病过程中     

麻风菌重组融合蛋白α—抗原的血清学活性

用麻风２的血清（Ｌ３８份、Ｂ１９份、Ｔ３６份）比较了α１－ＥＬＩＳＡ、α２－－ＥＬＩＳＡ与ＰＧＬ－Ｉ－ＥＬＩＳＡ法，结果各型患者血清中的抗何不工分别为：α１－抗原〉α２－抗原〉ＰＧＬ－Ｉ，尽管ＬＧ 血清中α１－怕的滴度明显高于其它两种抗原，但其阳性率在三种方法之间统计学上没有差别，分别为９７％，９２％和９４％；Ｂ和Ｔ型血清α１－ＥＬＩＳＡ法的阳性率明显高于其它两种方法，分别为８４％、５８％、６８％     

麻风菌重组融合蛋白α-抗原的血清学活性

用麻风患者的血清（Ｌ３８份、Ｂ１９份、Ｔ３６份）比较了α１－ＥＬＩＳＡ、α２－－ＥＬＩＳＡ与ＰＧＬ－Ｉ－ＥＬＩＳＡ法，结果各型患者血清中的抗体滴度分别为：α１－抗原＞α２－抗原＞ＰＧＬ－Ｉ，尽管Ｌ型的血清中抗α１－抗原的滴度明显高于其它两种抗原，但其阳性率在三种方法之间统计学上没有差别，分别为９７％，９２％和９４％；Ｂ和Ｔ型血清α１－ＥＬＩＳＡ法的阳性率明显高于其它两种方法，分别为８４％、５８％、６８％和４７％、３８％、３０％，以α１－ＥＬＩＳＡ法的敏感性最高。提示α１－ＥＬＩＳＡ在麻风血清诊断中有很大潜力，值得进一步扩大样本进行评价     

麻风杆菌重组α抗原的应用研究:α2-ELISA的建立

目的;以重组麻风杆菌α２融合蛋白为抗原,建立酶联免疫吸附试验,即α２－ＥＬＩＳＡ。方法：用麻风病人和健康正常人的血清评价了α２－ＥＬＩＳＡ中有关试剂及最适浓度,其敏感性与ＰＧＬ－１－ＥＬＩＳＡ进行了比较。结果：（１）挥发性缓冲液醋酸铵碳酸盐为α２抗原最佳包被液;（２）重组α２融合蛋白的最适包被浓度为５μｇ／ｍｌ;（３）显色剂ＯＰＤ的敏感性大于ＴＭＢ;（４）ＹＳＳ ＭＱ ＵＧＭ Ｗ ＴＬＤ ＩＧＥ     

银屑病患者白细胞流变性和白细胞CD18表达及血清sICAM—1浓度？…

目的 探讨白细胞流变性和细胞粘附分子（ＣＡＭＳ）表达与银屑病的关系。方法 采用ＥＬＩＳＡ法、红细胞变形能力测定 体外血栓血小板粘附两用仪检测了１１５例银屑２和８９例健康人白细胞ＣＤ１８表达、血清可溶性细胞间粘附分子－１（ｓＩＣＡＭ－１）浓度、白细胞滤过指数（ＬＦＩ）和白细胞粘附率（ＡＲ）的变化。结果 银屑病患者白细胞ＣＤ１８表达、ｓＩＣＡＭ－１浓度、ＬＦＩ和ＬＡＲ均明显增高，与对照组比较差异均有     

系统性红斑狼疮患者外周血单一核细胞中Th1型细胞因子的表达

目的 探讨系统性红斑狼疮（ＳＬＥ）患者中Ｔｈ１型细胞因子表达的情况。方法 用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）法检测了ＳＬＥ患者外周血单一核细胞（ＰＢＭＣ）中白介素２（ＩＬ－２）ｍＲＮＡ表达（４１例）和γ干扰素（ＩＦＮ－γ）ｍＲＮＡ表达（３１例）的水平。结果 与正常人相比,活动期ＳＬＥ患者中ＩＬ－２表达水平降低者占７８．０％,ＩＦＮ－γ表达水平降低者占８３．９％。活动期ＳＬＥ组ＰＢＭＣ中ＩＬ－２和     

用PGL—1和LAM—β对麻风复发做血清学监测

选３５例单用ＤＤＳ治愈平均已１８．６年的病人，相隔一年取两次耳垂血；１９９４和１９９５年共取血清７０份，分别用ＰＧＬ－１和ＬＡＭ－β抗原做ＥＬＩＳＡ。ＩｇＧ－ＬＡＭ－βＯＤ值〉）．１８，ＩｇＭ＿ＰＧＬ－１〉０．１６为阳性，ＩｇＧ－ＬＡＭ－β，ＢＬ－ＬＬ组２３份阳性（４８％）ＢＴ－ＴＴ组５份阳性（２３％）。ＩｇＭ－ＬＡＭ－１，ＢＬ－ＬＬ组２４份阳性（５０％），ＢＴ－ＴＴ组６份阳性（２７．６％）。所有     

用MDT后麻风病人及其接触者血中的抗PGI IgM抗体检测

推广应用ＭＤＴ后用ＮＴ－Ｏ－ＢＳＡ－ＥＬＩＳＡ检测了１７１５名麻风接触者和６例新病人血中的抗ＰＧＩ－ＩｇＭ抗体。１７１５例接触者中的抗体阳性率分别为：开始ＭＤＴ前３３．４％，用ＭＤＴ２－２４个月３２．８２％，用ＭＤＴ后４８个月２１．８４％（Ｐ＜０．００１）；６例新病人在推广ＭＤＴ５年时ＯＤ下降７２．７４％；连续观察２４３例抗体阳性的接触者，２－５年共发病７例（ＢＴ１例，ＢＬ４例，ＬＬ２例）。结果说     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.